Tempus ECG-AF vs iCAC Device
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if you need to proactively identify older patients at risk of developing new-onset atrial fibrillation within the next year, utilizing standard 12-lead ECGs. This tool is ideal for geriatric or internal medicine practices looking to enhance early detection and facilitate timely follow-up for AF in patients aged 65 or older without a prior AF diagnosis.
View Tempus ECG-AF →Choose iCAC Device if…
Choose the iCAC Device if your goal is to opportunistically assess a patient's coronary artery disease risk by quantifying coronary artery calcium from routine, non-contrast chest CT scans. This solution is particularly useful for radiologists and cardiologists seeking adjunctive information on cardiovascular disease burden from existing imaging data, without requiring dedicated cardiac CTs.
View iCAC Device →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | iCAC Device |
|---|---|---|
| Pricing | Contact vendor | Contact for pricing |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Software as a Medical Device (SaMD), integrates with PACS or DICOM router. Cloud-based (via Carebricks platform). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
iCAC DeviceWhile both tools integrate into existing healthcare systems, Tool B (iCAC Device) leverages a cloud-based platform (Carebricks) with explicit integration into PACS, DICOM routers, and EHRs. The Carebricks platform also offers a conversational AI interface (Carebricks Chat), suggesting a more interactive and user-friendly experience for clinicians. In contrast, Tool A (Tempus ECG-AF) is described as not having a dedicated user interface and relies on backend integration via APIs or file exchange, which may offer less direct clinician interaction.
Clinical Value
TieBoth tools offer significant clinical value by applying AI to address critical cardiovascular conditions. Tool A (Tempus ECG-AF) provides a predictive risk assessment for atrial fibrillation within 12 months, enabling proactive patient management. Tool B (iCAC Device) opportunistically identifies and quantifies coronary artery calcium from routine CT scans, extracting new diagnostic insights from existing data for early cardiovascular disease detection. Both contribute to improved patient outcomes through earlier identification and follow-up.
Pricing & Value
Tempus ECG-AFTool A (Tempus ECG-AF) clearly outlines the availability of CMS reimbursement with specific CPT codes and a Medicare rate, providing transparency and a clear path to financial viability for healthcare providers. Tool B (iCAC Device) only states 'contact for pricing' with no public details on reimbursement or specific rates, making its financial value proposition less transparent.
Enterprise Readiness
Tempus ECG-AFTool A (Tempus ECG-AF) explicitly states it is HIPAA compliant and offers a Business Associate Agreement (BAA), which are fundamental requirements for enterprise adoption in healthcare. While Tool B (iCAC Device) is FDA-cleared and deploys as a scalable cloud-based solution, it requires contacting the vendor for details regarding BAA and HIPAA compliance, indicating less immediate transparency for enterprise-level scrutiny.
Innovation
iCAC DeviceWhile both tools are innovative in their application of AI to cardiology, Tool B (iCAC Device) demonstrates a slightly higher degree of innovation through its ability to opportunistically detect and quantify coronary artery calcium from routine, non-cardiac CT scans. This approach extracts new diagnostic value from already acquired patient data without requiring additional dedicated procedures, representing a significant shift in screening paradigms. Tool A's predictive capability for future AF from ECGs is also highly innovative, but iCAC's opportunistic data utilization is particularly noteworthy.
Support & Docs
Tempus ECG-AFTempus (Tool A) provides explicit contact information for various support needs, including a dedicated cardiology support team via phone and email, and offers a 'Tempus Hub' with FAQs for other products, indicating a structured approach to user assistance. Bunkerhill Health (Tool B) provides a general contact email, but specific details about documentation or dedicated technical support channels for the iCAC Device are not as explicitly detailed in the available information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | iCAC Device |
|---|---|---|
| Product Name | Tempus ECG-AF | iCAC Device |
| Primary Detection Target | Patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. | Detects and quantifies coronary artery calcium from routine, non-contrast, non-gated chest CT scans. |
| Input Data Type | 12-lead ECG recordings | Routine, non-contrast, non-gated chest CT scans |
| Intended Use/Patient Criteria | For patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery; results interpreted in conjunction with other diagnostic information and clinical history. | Aids in early cardiovascular disease detection; provides adjunctive information to radiologists; supports opportunistic identification of CAC from existing CT scans. |
| Supported Specialties | Cardiology, Geriatrics, Internal Medicine | Cardiology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and iCAC Device.